Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chandrasekaran Padmapriyadarsini

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Eclinicalmedicine|December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in IndiaPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
The Journal of Infection|May 17, 2025
Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of LinezolidBella Devaleenal Daniel, Sivakumar Shanmugam, Rashi Mehta, et al.
The Indian Journal of Medical Research|February 6, 2026
Artificial intelligence for screening drug resistance in tuberculosisSucharitha Kannappan Mohanvel, Ramalingam Radhakrishnan, Prasaanth Balraj, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2024
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialChandrasekaran Padmapriyadarsini, Vikas S Oswal, Chetankumar D Jain, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Eclinicalmedicine|December 6, 2021
A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in IndiaPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
The Journal of Infection|May 17, 2025
Long term outcomes in drug resistant tuberculosis with Bedaquiline, Pretomanid and varying doses of LinezolidBella Devaleenal Daniel, Sivakumar Shanmugam, Rashi Mehta, et al.
The Indian Journal of Medical Research|February 6, 2026
Artificial intelligence for screening drug resistance in tuberculosisSucharitha Kannappan Mohanvel, Ramalingam Radhakrishnan, Prasaanth Balraj, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 28, 2024
Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical TrialChandrasekaran Padmapriyadarsini, Vikas S Oswal, Chetankumar D Jain, et al.
Human Vaccines & Immunotherapeutics|March 21, 2024
Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adultsPrasad S Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, et al.
Pageof 8